Caspofungin
کاسپوفانژین
🦠 Antiinfectives For Systemic UseEchinocandin antifungal
Market / country: 🇺🇸 USA
Cancidas (US)
🧮 Dose calculator
Invasive fungal infection (aspergillosis, candidaemia, cryptococcosis) — hospital · Regimen source: FDA Cancidas · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity (e.g. anaphylaxis) to any component. FDA Cancidas · 4
Important interactions
- • Cyclosporine: raised ALT — use only if benefit outweighs risk. FDA Cancidas · 5.3
Formulations
- 50 mg vial — powder for injection 🇺🇸 USA FDA Cancidas · 3
- 70 mg vial — powder for injection 🇺🇸 USA FDA Cancidas · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Cancidas · 8.1
“Risk Summary Based on animal data, CANCIDAS may cause fetal harm (see Data ) .”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Cancidas · 8.2
“Risk Summary There are no data on the presence of caspofungin in human milk, the effects on the breast-fed child, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Cancidas · 8.4
“The safety and effectiveness of CANCIDAS in pediatric patients 3 months to 17 years of age are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in pediatric patients, and additional data from prospective studies in pediatric patients 3 months to 17 years of age for the …”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Cancidas · 8.5
“Although the number of elderly patients was not large enough for a statistical analysis, no overall differences in safety or efficacy were observed between these and younger patients.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA021227
- DailyMed (FDA label)FDA Cancidas
- MedlinePlus (NIH)Caspofungin Injection
- WHO ATC/DDDJ02AX04
- Darooyab (Iran)Caspofungin
🇮🇷 Registered in Iran Darooyab · G-702/Caspofungin
Dosage forms with Iranian generic codes, per Darooyab.
- 06757 · CASPOFUNGIN 50MG 10ML VIAL · ویال کاسپوفونجین ۵۰ میلیگرم ۱۰ میلیلیتر
- 06758 · CASPOFUNGIN 70MG 10ML VIAL · ویال کاسپوفونجین ۷۰ میلیگرم ۱۰ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Cancidas · 3FDA Cancidas · 2.2FDA Cancidas · 2.4FDA Cancidas · 2.7FDA Cancidas · 2.3FDA Cancidas · 4FDA Cancidas · 5.3FDA Cancidas · SPL approval / marketing categoryFDA Cancidas · 8.1FDA Cancidas · 8.2FDA Cancidas · 8.4FDA Cancidas · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-702/Caspofungin
- Clinical review⚠ Unverified